Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by askretkaon Mar 19, 2024 9:24am
125 Views
Post# 35940197

RE:RE:RE:RE:Ramping up production, very positive sign

RE:RE:RE:RE:Ramping up production, very positive signActually if you look into the details of the head and neck cancer trials. They were stopped in some cases due to people having fevers. There's some speculation now that we know of the HOT and COLD  tumor theory that this may have been the drug Actually working.  It's sort of same deal that the recent breast cancer trial that some people dropped out due to fever that should have been managed with some basic meds. 

I think that's the reason Brad Thompson was fired for miss management of the Head Neck trials?  Matt did comment in one quarterly way back that some of the Head Neck tumor people were STILL ALIVE.

I think it's similar to the call that Matt got from a Pancreatic study that was considered a failure but a few patients were STILL ALIVE and were on their 32nd course of Pelareorep?

I honestly believe that there's a valid reason that PanCan gave us the 5 million for the mFOLFIRINOX Pelareorep Tecentriq study. There's probably a hundred or more companies or researchers that they could have given that money to. They did comment in one of last two quarterly reports that it was a long complex vetting process before they were chosen. 

Obviously there's a lot of people betting against ONC or don't believe that our little company can achieve a new standard of care in Pancreatic Cancer and possibly own that space and a couple others in the Gastric Cancer realm. Otherwise our stock price and Market Cap wouldn't be so low.

If you look at what's happening and read between the lines we could be on the verge of a very big upside run. The Anal cancer cohort has given us a strong hint. It's PELAREOREP and TECENTRIQ ONLY. NO CHEMO   and it's pretty much trippled the activity of Tecentriq in that cancer. 

The big wild card now is the mFOLFIRINOX trial coming up.
Success there WILL be a new standard of care in Pancreatic cancer and possibly pave the way for a Pelareorep NALIRIFOX treatment as well in Pancreatic Cancer.

That's my two cents worth and read on things at the moment.  CHEERS!!!!!!!!!!!!!!!!!!!!!!!!! 




<< Previous
Bullboard Posts
Next >>